西北地区单中心汉族人群食管鳞癌病人基因分布状况研究
|
摘要
目的探讨西北地区单中心汉族人群食管鳞癌病人基因分布状况。方法接受手术治疗的52例西北地区汉族人食管癌病人的病例标本,采用Iuminer液相芯片和FISH法检测。结果病人的18个食管癌相关基因分别为ERCC1、BRCA1、TYMS、RRM1、TUBB3、STMN1、TOP2A、EGFR、PDGFR、VEGFR1、VEGFR2、VEGFR3、KIT、HER2、IGF1R、PTEN、PD-L1及21基因,分析其表达水平与临床病例的关系,结果阳性表达为10个(阳性率55.2%),为ERCC1、BRCA1、TYMS、RRM1、TUBB3、STMN1、TOP2A、VEGFR1、HER2、PTEN,在阳性表达基因中,ERCC1、TUBB3、HER2、PTEN表达情况与肿瘤病理无关,并且低表达TYMS基因病人肿瘤淋巴结转移率和肿瘤分期显著高于中高表达者(P<0.05),RRM1基因表达与是否吸烟显著相关(P<0.05)。结论西北地区汉族人群食管癌基因分布呈现差异性表达特征。
Objective To investigate the gene distribution of esophageal squamous carcinoma in han population in northwest China.Methods 52 patients with esophageal squamous cancer who had undergone esophagectomy were studied.The clinical data and the results of genetic test of these patients were collected.The relationship between gene expression and the clinical pathological characteristics were studied.Luminer liquid-phase chip and FISH method were used.Results Eighteen esophageal cancer related genes,including ERCC1,BRCA1,TYMS,RRM1,TUBB3,STMN1,TOP2 A,EGFR,PDGFR,VEGFR1,VEGFR2,VEGFR3,KIT,HER2,IGF1 R,PTEN,PD-L1 and 21 gene,were tested and only 10 genes were positive expressed(positive rate 55.2%),including ERCC1,BRCA1,TYMS,RRM1,TUBB3,STMN1,TOP2 A,VEGFR1,HER2,PTEN.The expression levels of ERCC1,TUBB3,HER2 and PTEN had no significance correlation with clinicopathological characteristics in esophageal squamous cancer patients.The lymph node metastasis rate and tumor stage of low expression level of TYMS patients was statistically higher than high expression patients(P<0.05).The expression level of RRM1 was statistically associated with smoking(P<0.05).Conclusion The gene expression was specific in esophageal squamous cancer patients of Chinese Han population from single-center of northwest China and this study may supply the potential targets for the genetic treatment of esophageal squamous cancer.
Objective To investigate the gene distribution of esophageal squamous carcinoma in han population in northwest China.Methods 52 patients with esophageal squamous cancer who had undergone esophagectomy were studied.The clinical data and the results of genetic test of these patients were collected.The relationship between gene expression and the clinical pathological characteristics were studied.Luminer liquid-phase chip and FISH method were used.Results Eighteen esophageal cancer related genes,including ERCC1,BRCA1,TYMS,RRM1,TUBB3,STMN1,TOP2 A,EGFR,PDGFR,VEGFR1,VEGFR2,VEGFR3,KIT,HER2,IGF1 R,PTEN,PD-L1 and 21 gene,were tested and only 10 genes were positive expressed(positive rate 55.2%),including ERCC1,BRCA1,TYMS,RRM1,TUBB3,STMN1,TOP2 A,VEGFR1,HER2,PTEN.The expression levels of ERCC1,TUBB3,HER2 and PTEN had no significance correlation with clinicopathological characteristics in esophageal squamous cancer patients.The lymph node metastasis rate and tumor stage of low expression level of TYMS patients was statistically higher than high expression patients(P<0.05).The expression level of RRM1 was statistically associated with smoking(P<0.05).Conclusion The gene expression was specific in esophageal squamous cancer patients of Chinese Han population from single-center of northwest China and this study may supply the potential targets for the genetic treatment of esophageal squamous cancer.
引文
[1] 赫捷,邵康.中国食管癌流行病学现状、诊疗现状及未来对策[J].中国癌症杂志,2011,21(7):501-504.
[2] Depypere L,Coosemans W,Nafteux P,et al.Video-assisted thoracoscopic surgery and open chest surgery in esophageal cancer treatment:present and future[J].J Vis Surg,2017,17(3):30.
[3] Guo K,Wang WP,Jiang T,et al.Assessment of epidermal growth factor receptor mutation/copy number and K-ras mutation in esophageal cancer[J].J Thorac Dis,2016,8(7):1753-1763.
[4] Hildebrandt MA,Yang H,Hung M,et al.Genetic Variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy[J].J Clin Oncol,2009,27(6):857-871.
[5] Shahbaz Sarwar CM,Luketich JD,Landreneau RJ,et al.Esophageal cancer:an update[J].Int J Surg,2010,8(6):417-422.
[6] Tian J,Shang M,Shi SB,et al.Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma [J].Cancer Chemother Pharmacol,2015,76(4):829-834.
[7] Guo XF,Zhu XF,Zhong GS,et al.Lapatinib,a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2,potentiates the antitumor effects of cisplatin on esophageal carcinoma[J].Dis Esophagus,2013,26(5):487-495.
[8] Sohal DP,Rice TW,Rybicki LA,et al.Gefitinib in definitive management of esophageal or gastroesophageal junction cancer:a retrospective analysis of two clinical trials[J].Dis Esophagus,2015,28(6):547-551.
[9] Zhang L,Ma J,Han Y,et al.Targeted therapy in esophageal cancer[J].Expert Rev Gastroenterol Hepatol,2016,10(5):595-604.
[10] Wald O,Smaglo B,Mok H,et al.Future directions in esophageal cancer therapy[J].Ann Cardiothorac Surg,2017,6(2):159-166.
[11] Bang YJ,van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
[12] Kopp HG,Hofheinz RD.Targeted Treatment of Esophagogastric Cancer[J].Oncol Res Treat,2016,39(12):788-794.
[13] Liu SY,Chen W,Chughtai EA,et al.PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma[J].World J Gastroenterol,2017,23(14):2585-2591.
[14] Hanagiri T,Ono K,Kuwata T,et al.Evaluation of topoisomerase I/topoisomerase IIalpha status in esophageal cancer[J].J Uoeh,2011,33(3):205-216.
[2] Depypere L,Coosemans W,Nafteux P,et al.Video-assisted thoracoscopic surgery and open chest surgery in esophageal cancer treatment:present and future[J].J Vis Surg,2017,17(3):30.
[3] Guo K,Wang WP,Jiang T,et al.Assessment of epidermal growth factor receptor mutation/copy number and K-ras mutation in esophageal cancer[J].J Thorac Dis,2016,8(7):1753-1763.
[4] Hildebrandt MA,Yang H,Hung M,et al.Genetic Variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy[J].J Clin Oncol,2009,27(6):857-871.
[5] Shahbaz Sarwar CM,Luketich JD,Landreneau RJ,et al.Esophageal cancer:an update[J].Int J Surg,2010,8(6):417-422.
[6] Tian J,Shang M,Shi SB,et al.Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma [J].Cancer Chemother Pharmacol,2015,76(4):829-834.
[7] Guo XF,Zhu XF,Zhong GS,et al.Lapatinib,a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2,potentiates the antitumor effects of cisplatin on esophageal carcinoma[J].Dis Esophagus,2013,26(5):487-495.
[8] Sohal DP,Rice TW,Rybicki LA,et al.Gefitinib in definitive management of esophageal or gastroesophageal junction cancer:a retrospective analysis of two clinical trials[J].Dis Esophagus,2015,28(6):547-551.
[9] Zhang L,Ma J,Han Y,et al.Targeted therapy in esophageal cancer[J].Expert Rev Gastroenterol Hepatol,2016,10(5):595-604.
[10] Wald O,Smaglo B,Mok H,et al.Future directions in esophageal cancer therapy[J].Ann Cardiothorac Surg,2017,6(2):159-166.
[11] Bang YJ,van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
[12] Kopp HG,Hofheinz RD.Targeted Treatment of Esophagogastric Cancer[J].Oncol Res Treat,2016,39(12):788-794.
[13] Liu SY,Chen W,Chughtai EA,et al.PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma[J].World J Gastroenterol,2017,23(14):2585-2591.
[14] Hanagiri T,Ono K,Kuwata T,et al.Evaluation of topoisomerase I/topoisomerase IIalpha status in esophageal cancer[J].J Uoeh,2011,33(3):205-216.